Welcome to our dedicated page for China SXT Pharmaceuticals SEC filings (Ticker: SXTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
China SXT Pharmaceuticals filings document foreign private issuer disclosures for a Nasdaq-listed specialty pharmaceutical company focused on Traditional Chinese Medicine Pieces and TCM Homologous Supplements. The company’s Form 6-K reports cover material events, securities purchase agreements, registered direct offerings, Class A ordinary shares, pre-funded warrants, and shelf registration references tied to its capital-raising activity.
The filings also record shareholder-meeting materials, proxy documentation, amendments to the memorandum and articles of association, and the creation of a dual-class share structure with Class A Ordinary Shares and Class B Ordinary Shares. These disclosures frame SXTC’s governance, voting rights, security structure, offering documents, and related legal opinions as a British Virgin Islands company reporting under Form 20-F status.
China SXT Pharmaceuticals, Inc. (SXTC) has filed an amended Form F-3 to register 157,500,000 Class A Ordinary Shares for resale by Smart Mart Limited. These shares may be issued to Smart Mart to satisfy balances of pre-funded "Pre-Paid Purchases" under a July 3, 2026 Securities Purchase Agreement with up to $31,500,000 aggregate principal (before a $1,500,000 original issue discount). The resale is subject to a 9.99% beneficial ownership cap.
The conversion price per share is the lower of 50% of the Nasdaq closing price on signing or 50% of the lowest closing price in the prior 180 trading days, but not below a $0.20 floor price. SXTC receives no proceeds from resales, but previously received cash from the Pre-Paid Purchases; Smart Mart will receive sale proceeds, while SXTC bears registration costs. The commitment period runs until the earlier of two years from initial closing, aggregate purchase proceeds of $30,000,000, or termination. The filing highlights substantial dilution risk, potential Nasdaq delisting risk, PRC regulatory and VIE-structure uncertainties, and HFCAA-related delisting risk for this China-based holding company.
China SXT Pharmaceuticals, Inc. (SXTC) reports an amendment to its financing arrangement with an institutional investor. The company previously agreed to issue one or more pre-paid purchases with an aggregate principal amount of up to $31,500,000 (before a $1,500,000 original issue discount) for purchases of Class A ordinary shares at a price not below a $0.20 per-share floor.
After a 1-for-80 share consolidation of the Class A ordinary shares on August 10, 2026, the floor price was adjusted to $16.00 per share under the pre-paid purchase terms. On August 27, 2026, the company and the investor executed Amendment No. 1 to reduce the floor price back to $0.20 per share. In connection with this amendment, the company filed Amendment No. 1 to its Form F-3 registration statement, and this report is incorporated by reference into the company’s existing Form S-8 and Form F-3 registration statements.
China SXT Pharmaceuticals, Inc. completed a registered direct offering of 4,500,000 Units, each consisting of one Class A ordinary share and one common warrant, at $2.00 per Unit, generating aggregate gross proceeds of $9,000,000 before fees and expenses.
Each Warrant is immediately exercisable at $3.20 per Class A ordinary share and expires one year after issuance, with cashless exercise and a "zero exercise price" option under which up to 63,000,000 Class A ordinary shares may be issued in total under the Warrants. Univest Securities, LLC acted as placement agent, earning a 7.0% cash fee on gross proceeds plus up to $50,000 of expenses, in an offering conducted under the company’s effective Form F-3 shelf registration.
China SXT Pharmaceuticals Inc. is conducting a primary offering of up to 4,500,000 Units, each consisting of one Class A Ordinary Share and one Ordinary Warrant, at $2.00 per Unit, for aggregate gross proceeds of up to $9,000,000. The company is also registering up to 63,000,000 Class A Ordinary Shares issuable upon exercise of the 4,500,000 Ordinary Warrants, which carry a $3.20 initial exercise price, cashless exercise, and a “zero price exercise” feature tied to VWAP and a $0.40 Floor Price.
The company expects to receive approximately $8.28 million in net proceeds after placement fees and expenses, to be used for working capital and general corporate purposes. A 7.0% cash fee will be paid to Univest Securities, LLC as placement agent. There is no minimum offering amount and no escrow arrangement.
Class A Ordinary Shares outstanding were 38,218,077 before the offering and are projected to reach 105,718,077 assuming full issuance of Units and zero price exercise of all Warrants, implying substantial potential dilution. The company highlights legal and operational risks from its China-based VIE structure and evolving PRC and U.S. regulations, including the HFCAA.
China SXT Pharmaceuticals, Inc. filed a Form F-3 prospectus to register the resale of up to 157,500,000 Class A Ordinary Shares by Smart Mart Limited. Those shares represent the quotient of a $31,500,000 aggregate principal Pre-Paid Purchase program (less a $1,500,000 original issue discount) and are subject to a 9.99% beneficial ownership cap per the Securities Purchase Agreement.
The Selling Shareholder will receive all proceeds from resales and the Company will not receive proceeds but will pay registration costs. The purchase-price mechanics use a 50% discount to specified Nasdaq closing-price measures with a $0.20 floor price. The prospectus discloses VIE structure risks, PRC regulatory uncertainty and HFCAA inspection considerations. As of the prospectus date, 38,218,077 Class A Ordinary Shares were issued and outstanding.
China SXT Pharmaceuticals entered a securities purchase agreement with an institutional investor for up to $30,000,000 in pre-paid purchases of Class A ordinary shares. An initial pre-paid purchase of $3,150,000 principal, less a $150,000 original issue discount, is expected to close on July 6, 2026.
During a two-year commitment period, the company may request additional pre-paid purchases between $250,000 and $3,000,000 each, with a five percent original issue discount and interest at 7% per annum. The investor can acquire shares at 50% of specified market prices, subject to a $0.20 floor price and a 9.99% beneficial ownership cap.
The company engaged Univest Securities as exclusive placement agent, agreeing to pay a 4.5% cash fee on gross proceeds, a 0.5% expense reimbursement, and up to $50,000 of additional expenses. In default, the outstanding balance may be accelerated with interest up to 18% per annum or the legal maximum.
China SXT Pharmaceuticals, Inc., a British Virgin Islands holding company for China-based traditional Chinese medicine operations, filed its annual Form 20-F for the year ended March 31, 2026. The report explains that investors hold shares in the offshore entity while business is conducted through PRC subsidiaries and a VIE structure, which depends on contractual agreements that face legal and regulatory uncertainties in China.
The filing highlights significant risk factors, including limited working capital requiring additional financing, heavy reliance on a single customer for most revenue, exposure to PRC regulatory, foreign exchange and tax regimes, and extensive dependence on key personnel. It also describes two recent reverse stock splits and the adoption of a dual-class share structure that grants Class B shares fifty votes per share, concentrating voting power while Class A Ordinary Shares continue to trade on the Nasdaq Capital Market.
China SXT Pharmaceuticals, Inc. entered into a Sales Agreement with Univest Securities, LLC to sell its Class A ordinary shares in an at-the-market offering of up to $100,000,000. Univest will act as sales agent and/or principal under specified written instructions from the company.
The commission for sales where Univest acts as sales agent is 3.00% of gross proceeds, and the company will reimburse $0.003 per share for certain trading and exchange fees and other expenses subject to limits. The ATM program is registered on the company’s Form F-3 shelf and can be terminated by either party on written notice.
China SXT Pharmaceuticals, Inc. is offering up to $100,000,000 of Class A Ordinary Shares in an at-the-market offering under a Sales Agreement with Univest Securities, LLC dated June 1, 2026. The shares may be sold from time to time at market prices through Univest as agent or principal.
The Sales Agreement pays Univest a 3.0% commission and treats Univest as an underwriter for Securities Act purposes; the offering proceeds are to be used for general corporate purposes. As of May 29, 2026, there were 38,218,077 Class A Ordinary Shares outstanding.
China SXT Pharmaceuticals, Inc. entered into a Securities Purchase Agreement with non-U.S. investors for a private placement of 3,500,000 Class A ordinary shares and 3,500,000 warrants. The warrants are immediately exercisable at $1.00 per share and have a five-year term.
The transaction closed on May 2, 2026 and generated gross proceeds of $3.5 million before expenses. The company plans to use the net proceeds for working capital and general corporate purposes. The securities were issued under Regulation S to purchasers who represented they are not U.S. persons.